Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-18 pm EDT
249.70 USD   -0.35%
08/18AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
08/17AMGEN INC. : Ex-dividend day for
FA
08/16AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act”
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis

06/06/2022 | 11:50am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about AMGEN INC.
08/18AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits ..
AQ
08/17AMGEN INC. : Ex-dividend day for
FA
08/16AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/16AMGEN CHRONICLES : Fresh Water and Fresher Ideas About Sustainability in Puerto Rico
PU
08/12AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11Senate finance committee chairman wyden sends amgen letter inqui…
RE
08/09Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rat..
MT
08/08AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 162 M - -
Net income 2022 6 252 M - -
Net Debt 2022 27 064 M - -
P/E ratio 2022 21,2x
Yield 2022 3,11%
Capitalization 134 B 134 B -
EV / Sales 2022 6,14x
EV / Sales 2023 5,83x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 249,70 $
Average target price 250,10 $
Spread / Average Target 0,16%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.10.99%133 572
JOHNSON & JOHNSON-2.51%440 598
ELI LILLY AND COMPANY14.66%301 034
PFIZER, INC.-17.73%276 521
ROCHE HOLDING AG-16.47%273 077
ABBVIE INC.4.35%250 080